A systematic review on different models of inducing obesity in animals: Advantages and limitations

Joseph Bagi Suleiman, Mahaneem Mohamed, Ainul Bahiyah Abu Bakar
Department of Physiology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Malaysia.

ABSTRACT
Several animals have been in the limelight of basic research associated with metabolic diseases like obesity. Obesity can be considered as a significant public health concern in the world. It raises the chances for a variety of disease conditions that includes diabetes, hypertension, liver disease, and cancers, which, in turn, decreases the overall lifespan of adult men and women. The World Health Organization has considered obesity as a global epidemic. Researchers have made several attempts to classify human obesity, but none have been successful. Animal obesity can be classified based on their etiology; however, till now, no animal model of obesity can replicate models of the human condition, they have only provided clues into the causes, afterwards, and preventive remedy to human adiposity. Over the years, there are varieties of animal models used to induce obesity. Some of them include monogenetic, polygenetic, surgical, seasonal, and other models of obesity. Apart from the advantages of these models, most of them are accompanied by limitations. The primary purpose of this review is, therefore, to highlight the several models with their advantages and limitations. By knowing the benefits and limitations of animal models of obesity, researchers may be at liberty to select the appropriate one for the study of obesity.

Introduction

Obesity is one of the worrisome health issues in advanced societies; it is a complex disorder that involves an excessive amount of body fat [1,2]. Obesity is characterized by an increased body mass index (BMI) of 30 kg/m² and above [3,4]. It is not just a cosmetic concern but is associated with other health diseases, such as hypertension, coronary heart disease, and diabetes [5]. Besides, it also associates with respiratory and prolonged musculoskeletal problems, lumbago, subfertility, and skin disease. For the past 30 years, its prevalence has increased tremendously [6], especially in the developing countries leading to the manifestation of obesity and its comorbidities like diabetes, which stimulated the mixture of the two words as “diabesity.” Hence, to battle obesity, the improvement of non-toxic and effective therapeutics is required [7]. Over the years, the use of animal models remains indispensable for finding, authenticating, and making effective original therapeutics for their harmless use in humans.

Similarly, it brings a desirable transition from the research done in the laboratory to new ways of treating patients. Consequently, the advantage of using animals’ models is that they can be kept up in strictly controlled conditions, fed with standard diet regimen, and kept under conditions without pathogens or germs. However, the limitation of animal models is that there is no affirmation that conditions which are externally comparable in animals and man are comparable at their fundamental level. In recent times, researchers have been faced with problems of selecting suitable animal models, thus having a very great number of contradicting factors and drawing inappropriate conclusions. Distinctive animal obesity models, ranging from monogenetic models to surgical models are significant in examining the conceivable etiology, pathogenesis, and treatment of the obesity condition in people, gave both the favorable advantages and limitations are completely comprehended [8]. This review thus aims at analyzing the various animal models of inducing obesity, their advantages,
and limitations. Information on keywords were gotten from EBSCOHOST, Google Scholar, Science Direct, SCOPUS, Springerlink, and PubMed databases from 2000 to 2019 based upon which the animal models were reviewed.

**Classification of obesity**

Excessive aggregation of fat in the body causes obesity bringing about negative impacts on the health of the individual [9]. Waist Circumference (WC), Waist–Hip Ratio (WHR), and BMI are the components utilized in the analysis of obesity. WHR is a potential marker of other increasingly severe health conditions. According to the World Health Organization, abdominal obesity is characterized as a WHR of more than 0.85 and 0.90 for females and males, respectively [10].

Similarly, females with WHR of more than 0.8 and males with more than 1.0 are at a higher risk for health problems. WHR has been demonstrated to be a superior indicator of cardiovascular illness than WC and BMI. WHR, which shows the central body fat distribution, is recently proved to be a marker for the risk of health problems. WHR can be calculated by dividing WC with the hip circumference.

Based on the clinical guideline for the identification, assessment, and management of obesity, adult patients are classified according to their co-morbidity risk status. Classification of Diseases Ninth Revision (ICD-9) is utilized to recognize persistent co-morbidities [11]. In Organization for Economic Co-operation and Development (OECD) countries, about half of the adults are having BMI ≥ 25 Kg/m² or overweight [12,13]. Table 1 summarizes the classification of overweight, obesity, and WC. Different types of obesity classified based on their origin have been identified (Table 2). Overweight is due to taking more food than the individual’s activity level, which can increase fat storage (exogenous) or due to dysfunction of metabolic or hormonal systems (endogenous).

### Table 1. Classification of overweight and obesity by BMI, WC and associated disease risk.

| BMI (kg/m²) | Obesity class | Disease risk * (relative to normal weight and waist circumference) |
|-------------|---------------|-------------------------------------------------------------------|
|             |               | Men ≥40 in (102cm) | Women ≥35 in (88cm) | >40 in (102cm) | >35 in (88cm) |
| Underweight | < 18.5        |               |                   |                |              |
| Normal      | 18.5 – 24.9   | Increased      |                   |                |              |
| Overweight  | 25.0 – 29.9   |               |                   |                |              |
| Obesity     | 30.0 – 34.9   | High           |                   | Very high      |              |
|             | 35.0 – 39.9   | Very high      |                   | Very high      |              |
| Extreme obesity | 40            | Extremely high |                   | Extremely high |              |

Adapted from World Health Organization [10]. BMI, Body Mass Index, *Disease risk for type 2 diabetes, hypertension, and coronary heart disease

**Mechanisms of several diseases in obesity**

Increased adipocytes have detrimental consequences on the pancreas, liver, kidneys, brain, heart, reproductive organs, muscles, and joints. The synthesis of adipokines triggers the proinflammatory cytokines, which impairs insulin in the pancreas leading to inflammation and consequently, Type 2 diabetes becomes inevitable [21]. The excessive production of lipids accumulates in the liver tissues causing increased lipotoxicity, which results in fatty liver disease, steatohepatitis, and cirrhosis. Similarly, increased adipocytes lead to mechanical stress on the kidneys, muscles, and joints resulting in renal compression and mechanical load on the joints, respectively, which ultimately leads to kidney failure and osteoarthritis [22]. The increased insulin resistance affects the brain by increasing neuronal insulin which also triggers the leptin action to cause neuronal inflammation and ultimately leading to hippocampal neurodegeneration and memory impairment. The effect of increased adiposity on the heart results in fat accumulation on the myocardium. This process increases triglycerides hydrolysis to form free fatty acids and causes dyslipidemia. This, in turn, leads to coronary heart disease [23]. Furthermore, reproductive systems are not spared, as the accumulation of fats in reproductive organs causes the release of reactive oxygen species, resulting in decreased sexual behavior, performance, and fertility. The mechanism through which obesity can cause several diseases is summarized in Figure 1.

**Epigenetic considerations in obesity**

Epigenetics is the alteration in a chromosome that damages the activity of a gene for which its expression can be inheritable by offspring. These alterations may include the addition of methyl, carboxyl, and hydroxyl groups to the DNA nucleotides. Recently, epigenetics suggests that obesity in males alters offspring’s metabolic and reproductive phenotypes by re-adjusting of spermatogonial stem cells.
These effects are also called epigenetic effects and were first discovered in human models. However, animal models still can give a significant model to investigate the mechanisms because it is ethically wrong to impose restrictions on human fetuses, while small animals can make the timescale effect possible to study. In a study carried out by Fraga et al. [25], monozygotic twins are epigenetically identical for some time in their lives, but with time notable changes were visible in their DNA and histone acetylation. Such alterations induced by the environment may have effects on their BMI. Besides, in research done in the Netherlands, in utero and early childhood, exposure to starvation had higher adverse effects on weight and height during adulthood [26].

**Models of inducing obesity in animals and their advantages and limitations**

There are several models of producing obesity in animals, which can be classified as (1) Genetic and (2) Non-genetic. Genetic models include monogenic, polygenic, and transgenic models, while the non-genetic models consist of dietary, exotic, large animals, and surgical models (Fig. 2).

**Monogenic model of obesity**

The monogenic model provides a unique insight into the organic mechanisms that lead to obesity [27]. Monogenic obesity is due to a mutation(s) in the leptin-melanocortin pathway [28]; hence, a few investigations have established that a minimum of 10 single gene impairments can cause obesity and single gene impairment can also result in dysregulation in different modes of energy expenditure [29]. Mutations that occur at the leptin and its receptors are typically found in obesity (ob/ob) mouse [30,31], diabetic (db/db) mouse [32], s/s mouse [33], Zucker (fa/fa) [34], and Koletsky obese rats [35], other monogenic models that have downstream deficits on the leptin receptor are, Wistar Kyoto fatty rats [36], POMC knock out [37,38], POMC/ agouti-related peptide (POMC/AgRP) knockout mice [39], melanocortin 4 receptor (MC4R) knockout mice [40], melanocortin 3 receptor (MC3R) knockout [41] in mice, agouti-related peptide (AgRP) overexpression [42,43] (Fig. 2). The ob/ob mouse model provides the molecular basis for obesity study; the obese gene was identified in 1949 in the Jackson Laboratory by researchers who discovered it accidentally [44]. The monogenic model is the most used. The studies have revealed that mice can attain a weight three times more than unaffected mice. It was found that the obese mice had enlargement of the pancreas and increased production of insulin, leading to hypercorticosteronemia, insulin resistance, hyperglycemia, hyperinsulinemia, and hypothyroidism as well as infertility [45]. Consequently, db/db mouse model also provides the molecular basis for obesity study. It was discovered in 1966 at the Jackson Laboratory, and the model has been used for over 50 years. In the gene of leptin receptor of these mice, the mutation occurs at G-to-T point, which leads to diabetes, dyslipidemia, high leptin, and insulin levels and insulin resistance. Besides, at the age of 8 weeks, they develop hyperglycemia. They are commonly used as type 2 diabetes animal model [46].

In s/s mouse model, there is a mutation that aims to disturb a transcription factor named STAT3, a fundamental component for the long-form signaling pathway of the leptin receptor [47,48]. They create inflexible insulin resistance in the liver yet are less hyperglycemic. Similarly, mutation of the leptin receptor (fa/fa) occurs in Zucker and Zucker Diabetic Fatty rats. They build up a phenotype of hyperphagia, while Koletsky rats change leptin receptor [49] in which it was obtained by transferring fa gene from Zucker fatty rats with 13 M strain to Wistar Kyoto rats that had impaired glucose

| Types of obesity                  | Sex                  | Body region affected                | Diseases associated with                                      | References |
|----------------------------------|----------------------|-------------------------------------|--------------------------------------------------------------|------------|
| Central/abdominal, android or apple | Male                 | Abdomen                             | Metabolic disorders                                          | [14]       |
| Peripheral/visceral, gynaecoid or pear | Female               | Buttocks, hips, and thighs           | Infrequently associated with metabolic disorders              | [1]        |
| Diffuse                          | Both                 | Whole body                          | -                                                            | [15]       |
| Localized                        | Both                 | Skin (redundant cutaneous mantle)    | Barraquer-Simons Syndrome, lipodystrophic disorders           | [16]       |
| Formerly obese                   | Both                 | Skin (redundant cutaneous mantle)    | fatty liver disease, Type 2 diabetes, asthma, fatty liver disease, cardiovascular disease | [17]       |
| Childhood                        | Children, adolescent | Whole body                          | high blood pressure or diabetes                              | [18]       |
| Morbid                           | Both                 | Whole body (BMI of more than 40)     | high blood pressure or diabetes                              | [19]       |
| Sarcopenic                       | Both                 | Low muscle mass, muscle strength, and high fat | high blood pressure or diabetes                              | [20]       |
tolerance. WFR is obese early in its life and has diseases related to obesity, like type 2 diabetes, hyperlipidemia, and hyperinsulinemia.

POMC, located in the hypothalamic arcuate nucleus, is a precursor of alpha-melanocyte-stimulating hormone (αMSH), which is the target of leptin and its absence usually leads to obesity [50]. Similarly, the mice with POMC/AgRP knockout often possess double knockout for AgRP and POMC. They develop obesity during increased eating because of AgRP acting on the MC4 receptor. The

| S/n | Type of Model | Type of Animal | Ecological classification | Advantages | Limitations |
|-----|--------------|----------------|--------------------------|------------|-------------|
| 1.  | Monogenic    | Mice and rats  | Genetic                  | • Very reliable and effective  
• Short generation interval  
• Low cost of maintenance and phenotype measurement  
• Ability to make designed mating and raise very large populations  
• Ability to control environmental factors to enable low density lipoprotein (LDL) experiments  
• Well organised molecular marker map | Requires technical knowhow  
• Differ from humans in energy partitioning and fat deposition  
• They are not a representative of human diseases |
| 2.  | Polygenic    | Mice           | Genetic                  | • Technique does not require prior knowledge  
• Frequently used model  
• Very affordable and effective  
• They are the more realistic model of human obesity | They do not have a natural obese  
control  
• Poor standardization  
• Long duration  
• Time consuming  
• Small size of mice causes experimental limitations |
| 3.  | Transgenic   | Mice           | Genetic                  | • Very reliable and effective  
• Targeted at a particular gene  
• There are available genetic tools | Requires technical know how |
| 4.  | Diet-induced | Mice and rats  | Nutritional              | • It is a combination of genetic and dietary influences  
• Quick induction of obesity and insulin resistance  
• Strong similarity to human situation  
• Cost effective  
• Best stimulation of all aspects of human metabolic syndrome X | Poor standardization  
• Long duration  
• They sometimes become overtly obese |
| 5.  | Exotic       | Seal and bats  | Nutritional              | • They are non-human primates  
• They are non-standard small rodents that undergo cycles of seasonally-induced fat storage | The tools for exploring genetic basis have not been developed  
• Unable to establish laboratory colonies |
| 6.  | Non-human primates | Macaques, rhesus monkey and baboons | Nutritional | • Anatomy and physiology are similar to humans It has translational relevance  
• It is possible to conduct blood sampling endoscopy and laparoscopic biopsies | Costly to maintain  
• Limited approved facilities  
• Long life cycle and uniparity |
| 7.  | Seasonal     | Hamsters       | Environmental            | • They exhibit photoperiods | Poor standardization |
| 8.  | Non-mammalian | Fish except zebra fish | Nutritional | • Short life cycle  
• Low maintenance cost | Distinct anatomy and physiology |
| 9.  | Large animals | Dogs, pigs and cats | Nutritional | • Similar to humans  
• Available genetic tools similar to humans  
• Cannulation is possible  
• Pharmacokinetics similar to humans  
• It’s a relatively novel model | Very complex  
• Specialized facilities needed  
• Long life cycle  
• The model is not well characterized |
| 10. | Surgical     | Rats           | Neural and endocrine     | • Very reliable and effective  
• Avoid effect of cytotoxic chemicals on other body organs | Requires technical know how  
• Operative procedures  
• High Very difficult to locate the VMH, PVN and ARC of the brain  
• Requires post-operative procedures  
• High mortality usually occurs |
Figure 1. Summary for the recommended hypotheses on the mechanisms through which obesity can cause several diseases.

Figure 2. Schematic diagram showing the obesity models. Legend: 11beta HSD-1: 11beta-hydroxysteroid dehydrogenase type 1; AgRP: agouti-related peptide overexpression; ARC: Arcuate Nucleus; C3H: C3H/HeJ mice; CRF: corticotrophin releasing factor; db/db: diabetic mouse; DIO: diet-induced obese; DR: diet resistant; GLUT4: glucose transporters 4; HFD: high-fat diet; HS: high-sucrose; KK: Kuo Kondo; MC3R: melanocortin 3 receptor knockout in mice; MC4R: melanocortin 4 receptor knockout mice; MCH: melanin concentrating hormone; NPY: Neuropeptide-Y; NZO: New Zealand Obesity; ob/ob: obesity mouse; OLETF: Otsu Long Evans Tokushima Fatty; POMC/AgRP: Pro-opiomelanocortin/agouti-related peptide knockout mice; POMC: Pro-opiomelanocortin knockout; POMC/AgRP: Pro-opiomelanocortin/agouti-related peptide knockout mice; POMC/AgRP: Pro-opiomelanocortin knockout; PVN: Paraventricular Nucleus; s/s mouse; TSOD: Tsumura and Suzuki obesity and diabetes; VMH: Ventromedial Hypothalamus; WDF: Wistar Kyoto fatty; WFR: wistar fatty rat; WHR: Waist-to-Hip Ratio; ZDF: Zucker Diabetic Fatty; ZFR: zucker fatty rats; αMSH: α-melanocyte-stimulating hormone.
MC4R knockout mice are created to target the MC4 receptor, thereby producing hyperphagia and morbid obesity \[51,52\], while the MC3R mice become obese when MC3 receptor is inactivated leading to increase fat accumulation \[53\]. Then again, MC4/MC3 receptor knockout mouse is those having double knockout on the MC3 and MC4 receptors. The obesity gene was taken to another level in 1992 with the discovery of ectopic agouti expression mice, which showed the cloning of the agouti gene.

Similarly, the AgRP expression mouse is the homologous of agouti receptor and a natural antagonist of αMSH at MC3 and MC4 receptor \[54\]. The monogenic model has proven to be the most reliable animal obesity models, until now it remains the most effective models. It is very cost effective and easy to maintain. It has also shown the ability to make a large population during mating; this is obvious in db/db and ob/ob mice. The model differs from human obesity in terms of energy partitioning and fat deposition and does not represent the obesity in human. It is very difficult to carry out; therefore, it requires a technical know-how \[55–57\].

**Polygenic model of obesity**

Inheritance of a quantitative phenotype is regulated and altered by a set of alleles at the different gene loci called polygenic variants, which also modifies the expression of a qualitative character. These variants vary in different individuals and play a role in body weight regulation \[58\]. Obesity develops when many polygenic variants in an individual increase body weight. It is worthy to note here that each polygene only contributes a fraction to the build-up of obesity \[59\]. A couple of these variants are found in obese individuals, as well as in normal-weight and lean individuals at a low level. The several types of polygenic models include New Zealand Obesity (NZO) mouse \[60\], Tsumura and Suzuki obesity and diabetes (TSOD) \[61\], C3H/HeJ mice (C3H) \[62\], Kuo Kondo (KK) \[42\], M16 \[63\], PBB/Ld \[64\], BRSUNT/N \[56\], 7L/IRE \[56\], Otsua Long Evans Tokushima Fatty (OLETF) \[65\], Sand rats, spiny mouse \[66\], and Tucu-tuco rats \[67\] (Fig. 2). The NZO group of mice displays obesity due to increased body weight within the initial 2 months, which may be due to hyperphagia related to leptin resistance even with hereditarily normal leptin and leptin receptors \[68\].

NZO mice have the severe phenotype, fat deposits, and diminished exercise activity relative to ob/ob and control mice \[69\]. Hence, obesity in NZO mice is because of hyperphagia, lack of physical activity, and diminished energy expenditure, which makes it similar to human obesity \[42\]. TSOD includes TSOD strain, which is obese with diabetes and Tsumura Suzuki non-obese strain, which is not obese \[70\]. M16 mouse model is an outbred model for the early development of polygenic obesity. It is created via the long-term selection of weight gain for 3 to 6 weeks. As compared to controls, it shows hyperphagia, hyperinsulinemia, and hyperleptinemia. At eight weeks of age, compared to controls, the females and males of this strain are hyperglycemic, in which they had 22% and 56% higher fasting plasma glucose levels, respectively \[42\].

KK Mouse is likewise a polygenic obesity model that shows insulin resistance, hyperinsulinemia, and hyperphagia with a moderate obesity at eight weeks of age. It was created with certain inbreeding for huge body size in Japan. The lethal yellow obese gene (Ay) was transferred to KK mouse strain to develop another strain named KKAy mouse which is broadly utilized for obesity and diabetes studies \[42\]. Another strain of rats for obesity models known as OLETF is created in Japan. Several weeks after delivery, these rats are typically hyperphagic with higher body weight leading to obesity. These rats are commonly utilized in diabetes and obesity studies. Obesity and diabetes-like disorder are reported in laboratory animal species like Israeli "sand rat" (Psammomys obesus), the "spiny mice" (Acomys cahirimus, A. russatus), the tucu-tuco (Etenomys taerum), and Djungarian hamster (Phodopus sungorus). Polygenic obesity remains the most frequently used animal model of obesity; it is cost-effective and does not require prior knowledge. Although this model remains a more realistic model of human obesity, it is time-consuming, lacks quality standardization, and the size of mice causes severe limitations of this model \[42,59,71\].

**Transgenic model of obesity**

To understand the mechanism, transgenic models of obesity have been created. These include corticotrophin-releasing factor (CRF) overexpressing mice \[72\], animals with enhanced GLUT4 transporters \[73\], mice with overexpression of serotonin 5-HT2c \[74\], melanin-concentrating hormone (MCH) \[75\], beta-3 adrenergic \[76\], neuropeptide-Y (NPY) 1 \[77\]/NPY2 \[78\]/bombesin 3/neuronal insulin receptor knockout (NIRKO) mice \[79\], and mice with overexpression of 11beta-hydroxysteroid dehydrogenase type 1 (11beta HSD-1) \[80\] (Fig. 2). CRF transgenic mice show central obesity with comorbidities, such as hair loss, thin skin, and muscle wasting. CRF is produced by the paraventricular nucleus (PVN) in the hypothalamus and is the main component of the hypothalamic-pituitary-adrenal axis \[81\].

Obesity usually develops in transgenic mice expressing GLUT4 in adipocytes by increasing nutrient substrate for adipogenesis and insulin-stimulated glucose transport. The number of adipocytes, not the size, is increased. Hence, they are used as models of fat-cell replication and differentiation during obesity development \[82\]. The transgenic mice overexpressing MCH develop obesity late in life. They are also associated with insulin resistance, hyperphagia, and high insulin level \[83\]. Similarly, mice with serotonin...
receptor (5-HT-2c) knockout that have a smaller number of functional 5-HT2C receptors develop hyperphagia \cite{84,85} in which adiposity and body weight are increased during weaning. Meanwhile, mice with knockout of neuropeptide-Y 1 receptor (NPY1R) have hyperphagia due to low energy expenditure accompanied by low uncoupling protein type-2 (UCP2) expression in white adipose tissue leading to obesity \cite{77}.

Furthermore, mice with NPY2R knockout develop paradoxical obesity \cite{86}. They become mildly hyperphagic and develop obesity. Mice with knockout of Bombesin 3 receptor (BRS3 ko) are hemizygous for this receptor, and they establish late-onset obesity because of hyperphagia and decreased metabolic rate \cite{87}. They also have hyperglycemia, insulin resistance, and a high level of insulin. NIRKO mice take moderate food, resulting in increased body weight, adiposity, hypertriglyceridemia, and high insulin level \cite{88}. The aftermath is conspicuous in mice exposed to high-fat diet (HFD), but female NIRKO mice develop obesity when on low chow. Mice with 11beta HSD-1 overexpression specifically in fat tissue have increased corticosterone level in fatty tissue, visceral obesity, and most metabolic syndrome features \cite{89}. As compared to wild-type controls, fat-specific 11beta HSD-1 transgenic mice consume food more, in which they have insulin resistance and the likelihood to develop diabetes. The transgenic model, on the other hand, has hereditary etiology, very reliable, and effective in the induction of obesity. One of its significant advantages is that it is targeted at a particular gene. There are so many genetic tools available for its processes, but unfortunately, it requires an in-depth knowledge of its procedures \cite{36,90-92}.

**Diet-induced model of obesity**

Diet-induced obese (DIO) rats develop obesity when given HFD, while diet-resistant rats have body weights like control rats when fed with a low energy diet. At 4 to 5 weeks of age, during they are lean and before their body weight starts to diverge, DIO rats become less sensitive to the hypophagic activity of leptin \cite{93}. It is evident that animals introduced to HFD usually develop obesity and can exhibit reduce levels of insulin and leptin sensitivity \cite{94}. Cafeteria diets are apparent imitations of models of human obesogenic foods. They result from excessive eating that is made up of increases in the energy expenditure, a result of sympathetic activation of brown adipocyte. Overconsumption of cafeteria diets means there are an increase in the frequency and average meal size.

These diets provide animals with a mixture of sugar, salt, and high fat drawn from solid foods \cite{95,96}. Additionally, in the high sucrose (HS) DIO rat model, the rats are fed with this diet or a modified HS diet for a few weeks. Visceral adipose tissue is enlarged by the exposure of rats to HS diet without necessarily increasing body weight and reducing glucose disposal rates. An increase in hepatic glucose, plasma glucose, and free fatty acids are all associated with this model. Lipidosis and swelling of hepatocyte mitochondria in the liver are found in HS rats \cite{97}. The advantages of the diet-induced model of obesity include having a combination of genetic and dietary influences on the animal; it can also be a quick way of inducing obesity and is insulin resistant. There is a substantial similarity to human obesity, and the model is cost-effective. The limitations of the model are poor standardization, long duration, and they are overtly obese.

**Exotic model of obesity**

The model comprises wild animals that go through original designs of disparity in their fat mass, such as seals and bats \cite{90}. However, the benefit of this model is influenced by the absence of instruments to investigate a genetic basis, and the animals present a huge challenge with regards to setting up research facility-based colonies for the experiments. The model is known for its efficacy and will likely give unique insights about the storage of body fat \cite{71}. Exotic models are non-human primates and non-standard small rodents that experience periodically induced fat storage and exhibit photoperiods. The main limitation of this model is its inability to establish laboratory colonies, and the tools for exploring its genetic basis have not been developed.

**Non-human primate model of obesity**

The non-human primate model exhibits obesity, which is similar to human obesity. It involves the old world’s monkeys, for example, macaques, rhesus monkeys, and baboons, which give appropriate and essential information related to human obesity \cite{90,92}. Rhesus monkeys raised in cages tend to have increased body weights and develop obesity with its comorbidities \cite{42}. Furthermore, when on food ad libitum, obesity is visible in macaques in an age-dependent manner. They also develop type 2 diabetes, as well as its complications. Their body inactivity increases the risk of obesity. Spontaneous obesity is also detected in wild baboons and free-ranging rhesus monkeys. Japanese monkey named *Macaca fuscata* also becomes obese without diabetes \cite{42}. The non-human primate model is fundamentally the same as the human model of obesity, and this is a direct result of its closeness in structure (anatomy) and function (physiology). The capacity to conduct blood sampling endoscopy and laparoscopic biopsies make the model very unique. However, its high cost of maintenance, lack of approved facilities, long life cycle, and uniparity have limited the use of this model.
**Seasonal model of obesity**

The seasonal model of obesity is closely related to human obesity in several ways. For instance, high fat-fed hamsters have similar findings in humans about the distribution of phospholipid classes, the activity of cholesterol ester transfer protein, and regulation of LDL receptor [98]. They are, therefore, suitable for the investigation of dyslipidemia and cholesterol metabolism. Diets consisting of 12%–15% of fat and 0.3%–0.5% of cholesterol induces dyslipidemia, hyperglycemia, and moderate obesity in hamsters. There are two kinds of hamster strains which can be used for the induction of dyslipidemia, namely, BioF1B hamsters and Lakeview Golden (LVG) outbred “Lakeview hamsters” (Charles River) [46].

**Large animals’ model of obesity**

Large animals’ model of obesity has a lot of resemblance to human obesity because it allows a broad metabolic phenotyping assessment of obesity. The examples of such large animals include dogs, pigs, and cats [42]. As compared to humans, domestic dogs may have an epidemic of obesity, which can be more extreme. HFD-induced obesity in dogs is characterized by insulin resistance, high insulin level, and impaired glucose tolerance. Obese cats develop type 2 diabetes with the presence of β-cell mass loss and islet amyloid [99]. On the other hand, dogs can have obesity within 4–12 weeks when they are free to access to (1) standard meat and chow diet, (2) meat and chow diet added with fat, or (3) commercial diet mixed with either high-fructose or high-fat or both ad libitum. Hyperphagia is maintained throughout the access, but higher energy intake is significant during the first 1–2 weeks [90].

The large animal model is the only animal obesity model that truly represents the human obesity. Their pharmacokinetics is similar to humans, and there are also available genetic tools for the model. In this model, cannulation is possible; however, the model is very complex and complicated as specialized equipment and facilities are required to carry out the processes. Besides, the animals have a long-life cycle and not well characterized. Likewise, the non-mammalian model has a meager cost of maintenance when compared to other models of obesity, it has a short life cycle, and however, its major limitation is its distinct anatomy and physiology which makes it challenging to study or used as an extrapolation with human to obesity.

**Surgical model of obesity**

The damage to arcuate nucleus (ARC), PVN, ventromedial hypothalamus (VMH), and ovariectomy are examples of surgical models of obesity. Electric current and monosodium glutamate (MSG) causes bilateral lesions of the hypothalamic nuclei, which results in hyperphagia, adiposity, and increased body weight. This model requires anesthesia and surgical skills. The rats are anesthetized and bilateral VMH lesions produced by electrical destruction using stereotaxic instrument [100]. Obesity can also be induced by the extensive lesions of the PVN, which eventually may result in hyperinsulinemia and insulin resistance in rats [101]. It is worthy to note; it is hard to perform selective surgical lesions of the ARC because of its location and anatomical shape. So far, most lesions are involved the whole mediobasal hypothalamus, involving the ventromedial area. As another option, induction of relatively selective damage of ARC neurons projecting to PVN and VMH can be done by giving MSG repeatedly to neonatal rats ten days after delivery. Obesity develops in these rats as they become hyperphagia and have hyperinsulinemia and insulin resistance [102].

Studies carried out in rats suggest that there is an abrupt hormone deprivation caused by oophorectomy (surgical removal of the ovaries) [103]. The reduction of hormone level such as estrogen level leads to obesity and its metabolic sequelae. The surgical removal of ovaries reduces the initial leptin levels and increases the same after 7 weeks. This resistance to leptin may increase the weight gain of the rats. Animal studies show a consistent correlation between bilateral oophorectomy and adiposity, total and LDL-cholesterol levels, and insulin resistance. The surgical model is very reliable and cost-effective. Its primary advantage is that the effect of cytotoxic chemicals on other organs of the body can be avoided [100]. However, the limitations of this surgical model outweigh its advantages as, for instance, the VMH, PVN, and ARC nucleus are very difficult to locate, and the procedure requires high technical knowledge and post-operative processes, and it has high mortality rate [91].

The induction of obesity in different animal models is influenced by a few factors, including biological, psychosocial, and environmental factors. Hence, it is justifiable that various limitations are established when analyzing results obtained from different obesity models in a laboratory and humans. Although animal models are a significant technique for examining the impacts of obesity and drug testing, it is essential to comprehend the limits of the model’s overall capacity to mimic the pathophysiology of obesity in humans. The advantages and limitations of animal models of obesity based on technical know-how, duration, life cycle, cost, effectiveness, shape, mortality rate, characterization, complexity, approved facilities, ability to form colonies, time consumption, standardization, and ability to represent human diseases are summarized in Table 3.

**Conclusion and future direction**

Over the years, the study of obesity has been improved utilizing animal models, which have revealed underlying causes, such as environmental, hereditary, physiological,
and epigenetic factors. Obesity animal models have also led to the studies of potential drugs and natural products in the management of obesity. They also play an essential role in studies to understand the fundamental physiological and genetic factors in the regulation of energy, perception of smell and taste, as well as the behavior in choosing the food. Besides, animal models provide an essential model for the development of pharmaceutical drugs and novel dietary interventions. Nevertheless, a few of these models have advantages that outweigh the limitations.

Acknowledgment
The authors would like to acknowledge the Malaysian Ministry of Higher Education (Fundamental Research Grant Scheme: 203.PPSR6171195) Malaysia and Universiti Sains Malaysia (USM), Malaysia, for giving the first author the USM graduate assistant scheme award for funding this review.

Competing interests
The authors declare that they do not have any competing interests.

Authors’ contributions
Joseph Bagi Suleiman participated in the design of the study, collated information, and wrote draft the manuscript. Mahaneen Mohamed conceived the study, participated in its design, and proofread the manuscript. Ainul Bahiyah Abu Bakar co-operated in writing and proofreading the paper. All authors read and approved the final manuscript.

References
[1] Rosso C, Mezzabotta L, Gaggiini M, Salomone F, Gambino R, Marengo A, et al. Peripheral insulin resistance predicts liver damage in non-diabetic subjects with nonalcoholic fatty liver disease. Hepatology 2016; 63(1):107–16; https://doi.org/10.1002/hep.28287
[2] Lee S, Paz-Filho G, Astronauti C, Licinio J, Wong ML. Is increased antidepressant exposure a contributory factor to the obesity pandemic? Transl Psychiat 2017; 6(3):e759; https://doi.org/10.2106/tp.2016.25
[3] Deurenberg P, Yap M, Van Staveren WA. Body mass index and per cent body fat: a meta analysis among different ethnic groups. Int J Obes 1998; 22(12):1164. https://doi.org/10.1038/sj.ijo.0800741
[4] Suleiman JB, Eze ED, Karimah MR, Iliya E. Assessment of body mass index and per cent body fat: a meta analysis among different ethnic groups. Int J Obes 1998; 22(12):1164. https://doi.org/10.1038/sj.ijo.0800741
[5] Yanovsky SZ, Yanovsky JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014; 311(1):74–86; https://doi.org/10.1001/jama.2013.281361
[6] Skinner AC, Ravanbakhsh SN, Skelton J, Perrin EM, Armstrong SC. Prevalence of obesity and severe obesity in US children, 1999–2016. Pediatrics 2018; 140(6). https://doi.org/10.1542/peds.2017-3459
[7] Wuenstel WG. Meta-analysis of the relationship between ethnicity, obesity, and type 2 diabetes of adult in urban populations of Central America. Int J Public Health Sci (IJPHS) 2012; 5(3):274–9.
[8] Heise TL, Katikireddi SV, Pega F, Garthleiner G, Penton C, Griebler U, et al. Taxation of sugar-sweetened beverages for reducing their consumption and preventing obesity or other adverse health outcomes. Cochrane Library 2016; https://doi.org/10.1002/14651858.CD012319
[9] Russo C, Sera F, Jin Z, Palmieri V, Homma S, Rundek T, et al. Abdominal adiposity, general obesity, and subclinical systolic dysfunction in the elderly: a population-based cohort study. Eur J Heart Fail 2016; 18(5):537–44; https://doi.org/10.1002/ejhf.1521
[10] Mohamed GA, Ibrahim SR, Elkhayat ES, El Dine RS. Natural anti-obesity agents. Bull Faculty Pharm, Cairo University 2014; 52(2):269–84; https://doi.org/10.1616/j.bfopcu.2014.05.001
[11] Wagner D, Büttner S, Kim Y, Gani F, Xu L, Margonis G, et al. Clinical and morphometric parameters of frailty for prediction of mortality following hepatopancreaticobiliary surgery in the elderly. Br J Surg 2016; 103(2); https://doi.org/10.1002/bjs.10037
[12] Pierre R. Investigating the association between body mass index and the incidence of coronary heart disease in the First National Health and Nutrition Examination Survey Epidemiologic follow-up study: Florida Agricultural and Mechanical University, Tallahassee, FL, 2016.
[13] Booth HP, Charlton J, Gulliford MC. Socioeconomic inequality in morbid obesity with body mass index more than 40 kg/m² in the United States and England. SSM-Population Health 2017; 3:172–8; https://doi.org/10.1016/j.ssmph.2016.12.012
[14] Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE, Sochor O, et al. Normal-weight central obesity: implications for total and cardiovascular mortality. Ann Intern Med 2015; 163(11):827–35; https://doi.org/10.7326/M14-2525
[15] Józsa LG. Obesity in the paleolithic era. Hormones 2011; 10(3):241–4; https://doi.org/10.14331/horm.20021315
[16] Datta G, Cravero L, Bocchiotti MA, Kefalas N. The plastic surgeon in the treatment of obesity. Obes Surg 2006; 16(1):5–11; https://doi.org/10.1007/9680920677522189
[17] Rossi EL, De Angel RE, Bowers LW, Khatib SA, Smith LA, Van Buren E, et al. Obesity-associated alterations in inflammation, epigenetics, and mammary tumor growth persist in formerly obese mice. Cancer Prevent Res 2016; 9(5):339–40; https://doi.org/10.1158/1940-6207.CAPR-15-0348
[18] Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA 2014; 311(8):806–14; https://doi.org/10.1001/jama.2014.732
[19] Kagan J, Balliro J, Dann M, Guterman L. Apparatus and methods for treatment of morbid obesity. Google Patents 2006.
[20] Goisser S, Kemmler W, Porzel S, Volkert D, Sieber CC, Bollheimer LC, et al. Sacropenic obesity and complex interventions with nutrition and exercise in community-dwelling older persons–a narrative review. Clin Interv Aging 2015; 10:1267; https://doi.org/10.1158/1940-6207.CAPR-15-0348
[21] Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes, Metab Synd Obes: Target Ther 2014; 7:587; https://doi.org/10.2147/DMSOS.S67400
[22] Heymsfeld SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med 2017; 376(3):254–66; https://doi.org/10.1056/NEJMra1514009
[23] Van Gaal L. Mechanisms linking obesity with cardiovascular disease. Diab, Obesity Metabol 2010; 12:21.
[24] El Salam MAA. Obesity, an enemy of male fertility: a mini review. Oman Med J 2018; 33(1):3; https://doi.org/10.5001/omj.2018.02
[25] Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005; 102(30):10604–9; https://doi.org/10.1073/pnas.050039102
et al. - J. Adv. Vet. Anim. Res., 7(1): 103–114, March 2020

[61] Ohta M, Fujinami A, Oshki K, Kohayashi N, Ohnishi K, Ohkura N. Ashitaba (Angelica Keiskei) Exudate Prevents Increases in Plasma Glucagon-Like Peptide-1 Induced by Obesity in Tsumura Suzuki Obese Diabetic Mice. J. Diet Suppl. 2018; https://doi.org/10.1080/19390211.2018.1458366:1-13

[62] Jackson EE, Rendina-Ruedy E, Smith BJ, Lacombe VA. Loss of toll-like receptor 4 function partially protects against peripheral and cardiac glucose metabolic derangements during a long-term high-fat diet. PLoS One 2015; 10(11):e0142077; https://doi.org/10.1371/journal.pone.0142077

[63] de Jong JM, Wouters RT, Boulet N, Cannon B, Nedergaard J, Petrovic N. et al. Animal models for assessing the impact of natural products on the aetiology and metabolic pathophysiology of Type 2 diabetes. Biomed Pharmacother 2017; 89:1242–51; https://doi.org/10.1016/j.biopharm.2017.03.010

[64] Hunt C, Lindsey J, Waldey S, (Eds.). Animal models of diabetes and obesity, including the PBB/Ld mouse. Fed Proc 1976; 35:1206–17.

[65] Ma W-W, Ding B-J, Yuan L-H, Zhao L, Yu H-L, Xiao R. Neuropeptide Y receptor gene expression in the primate amygdala predicts anxious temperament and brain metabolism. Biol Psychiatry 2014; 76(11):103–114; https://doi.org/10.1016/j.biopsych.2013.11.012

[66] Aerts E, Geets S, Sorber L, Beckers S, Verrijken A, Massa G, et al. Evaluation of a role for npy and npy2r in the pathogenesis of obesity by mutation and copy number variation analysis in obese children and adolescents. Am J Hum Genet 2018; 82(1):1–10; https://doi.org/10.1111/ajhg.12211

[67] Xiao C, Piñol RA, Carlin JL, Li C, Dang C, Cavaliere O, et al. Bombyxin-like receptor 3 (Br3) expression in glutamatergic, but not GABAergic, neurons is required for regulation of energy metabolism. Mol Metabol 2017; 6(11):1540–50; https://doi.org/10.1016/j.molmet.2017.08.013

[68] de Nascimento FV, Piccoli V, Beer MA, von Frankenberg AD, Crispim D, Gerchman F. Association of HSD11B1 polymorphic variants and adipose tissue gene expression with metabolic syndrome, obesity and type 2 diabetes mellitus: a systematic review. Diabetol Metab Syndr 2015; 7(1):38; https://doi.org/10.1186/s13098-015-0036-1

[69] Lang W, Goebel-Stengel M, Yuan PQ, Stengel A, Taché Y. Corticotropin-releasing factor overexpression in mice abrogates sex differences in body weight, visceral fat, and food intake response to a fast and alters levels of feeding regulatory hormones. Biol Sex Differ 2017; 8(1):2; https://doi.org/10.1186/s13293-016-0122-6

[70] Shepherd V, Orlovich D, Ashford A. Cell-to-cell transport via motile tubules in growing hyphae of a fungus. J Cell Sci 1993; 105(4):1173–8.

[71] Ludwig DS, Peterson KE, Gortmaker SL. Relation between consumption of sugar-sweetened drinks and childhood obesity: a prospective, observational analysis. Lancet 2001; 357(9255):505–8; https://doi.org/10.1016/S0140-6736(00)04041-1

[72] Heisker LK, Tecott LH. Knockout corner: neurobehavioural consequences of a serotonin 5-HT2C receptor gene mutation. Int J Neuropsychopharmacol 1999; 2(1):67–9; https://doi.org/10.1017/S1461145799001327

[73] Tecott LH, Sun LM, Akana SF, Stack AM, Lowenstein DH, Dallman MF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 1995; 374(6522):542–6.

[74] Naveilhan P, Hassan H, Canals M, Ekstrand AJ, Larefalk Å, Chaijani V, et al. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat Med 1999; 5(10):1188; https://doi.org/10.1038/13514

[75] Ohki-Hamazaki H, Watake K, Yamamoto K, Ogura H, Yamano M, Yamada K, et al. Mice lacking neuropeptide receptor subtype-3 develop metabolic defects and obesity. Nature 1997; 390(6656):165; https://doi.org/10.1038/36568

[76] Brüning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289(5487):2212–25; https://doi.org/10.1126/science.289.5487.2212

[77] Man IC, Su HY, Calle-Vallejo F, Hansen HA, Martínez JI, Inoglu NG, et al. Neuropeptide Y (NPY) receptor gene expression in the primate amygdala predicts anxious temperament and brain metabolism. Biol Psychiatry 2014; 76(11):850–7; https://doi.org/10.1016/j.biopsych.2013.11.012

[78] Speakman J, Hambly C, Mitchell S, Król E. Animal models of obesity. Obes Rev 2007; 8(s1):55–61; https://doi.org/10.1111/j.1467-789X.2007.00319.x

[79] York DA. Lessons from animal models of obesity. Endocrinol Metabol Clinics 1996; 25(4):781–800; https://doi.org/10.1016/S0089-8529(05)70534-6
[92] York DA. Animal models of obesity. Int Textbook Diabetes Mellitus, 2003.

[93] Willett WC, Leibel RL. Dietary fat is not a major determinant of body fat. Am J Med 2002; 113(9):47–59; https://doi.org/10.1016/S0002-9343(01)00992-5

[94] Hariri N, Thibault L. High-fat diet-induced obesity in animal models. Nutr Res Rev 2010; 23(2):270–99; https://doi.org/10.1017/S0954422410000168

[95] Cook JB, Hendrickson LM, Garwood GM, Toungate KM, Nania CV, Morikawa H. Junk food diet-induced obesity increases D2 receptor autoinhibition in the ventral tegmental area and reduces ethanol drinking. PLoS One 2017; 12(8):e0183685; https://doi.org/10.1371/journal.pone.0183685

[96] La Fleur S, Luijendijk M, Van Der Zwaal E, Brans M, Adan R. The snacking rat as model of human obesity: effects of a free-choice high-fat high-sugar diet on meal patterns. Int J Obes 2014; 38(5):643; https://doi.org/10.1038/ijo.2013.159

[97] Cao L, Liu X, Cao H, Lv Q, Tong N. Modified high-sucrose diet-induced abdominally obese and normal-weight rats developed high plasma free fatty acid and insulin resistance. Oxid Med Cell Longev 2012; 2012:1–9; https://doi.org/10.1155/2012/374346

[98] Reuter TY. Diet-induced models for obesity and type 2 diabetes. Drug Discov Today Dis Models 2007; 4(1):3–8; https://doi.org/10.1016/j.ddmod.2007.09.004

[99] Sclafani A. Animal models-etiologic classification. Int J Obes 1984; 8:491–508.

[100] Tokunaga K, Matsuzawa Y, Fujioka S, Kobatake T, Keno Y, Odaka H, et al. PVN-lesioned obese rats maintain ambulatory activity and its circadian rhythm. Brain Res Bull 1991; 26(3):393–6; https://doi.org/10.1016/0361-9230(91)90012-9

[101] Deng X, Feng X, Li S, Gao Y, Yu B, Li G. Influence of the hypothalamic paraventricular nucleus (PVN) on heart rate variability (HRV) in rat hearts via electronic lesion. Biomed Mater Eng 2015; 26(s1):S487–S95; https://doi.org/10.3233/BME-151338

[102] Secher A, Jelsing J, Baquero AF, Hedsker-Sørensen J, Cowley MA, Dalbøge LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Investig 2014; 124(10):4473–8; https://doi.org/10.1172/JCI75276

[103] Moak SP, Browning JR, Dai X, Hall JE, do Carmo JM. Reduced energy expenditure and increased sleep time contribute to development of ovariectomy-induced obesity in mice fed a high fat diet. FASEB J 2017; 31(1):1037.1.